Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Features
FEATURES
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Diagnosis and Management of Thrombocytopenia in Pregnancy
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Expert Q&A: The Current State of Gene Therapy for Hemophilia
Although gene therapy shows promise in curing hemophilia, questions about its efficacy, optimal administration, and outcomes remain.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
British Society of Hematology Guideline Update for Point-of-Care Testing in Hematology
Researchers reviewed currently available point-of-care technology and provided recommendations for standardizing use of this technology.
Updated Guidance on Managing Bleeding and Surgery on Antiplatelet Therapy
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Resting vs Activated Platelets: Why Knowing the Difference Makes Financial Sense
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
BAFF-R-CAR-T to Overcome Resistance: Q&A With Dr Hong Qin
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
As Survival Increases in Beta Thalassemia, Renal Complications Emerge
Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.
Advances in the Diagnosis of Type 1 von Willebrand Disease: Genetic Testing
Despite the increasing availability of gene sequencing, several barriers prevent it from having utility as a tool for diagnosis of type 1 von Willebrand disease.
Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Improving the Clinical Diagnosis and Classification of Gray Zone Lymphomas
Although gray zone lymphoma has distinct morphologic features, immunophenotyping can make classifying gray zone lymphoma challenging.
A New Era: Drug Development for Acute Myeloid Leukemia After the Approval of Venetoclax
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
The Role of Vitamin K Antagonists in Managing Thrombosis in Myeloproliferative Neoplasms
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
Current and Prospective Treatment Strategies for Myeloproliferative Neoplasms
Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.
Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Maintenance Therapy in Acute Myeloid Leukemia: An Overview
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Challenges in the Diagnosis and Management of Polycythemia Vera
Due to conflicting literature, there is currently no consensus on the appropriate standard of care for managing polycythemia vera.
Novel Management Strategies for Myelodysplastic Syndromes
Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Second-Line Treatment Options for Aplastic Anemia
Second-line treatment strategies for severe aplastic anemia include stem cell transplant, immunosuppressive therapy, and thrombopoietin mimetics.
Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
Frontline Treatment Strategies and Therapeutic Options for Mantle Cell Lymphoma
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Reducing Transfusion Burden and Addressing Unmet Needs in Beta Thalassemia
Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.
Nurses’ Guide to Managing Symptoms of Myeloproliferative Neoplasms
Oncology nurses discuss the importance of ongoing education on the treatments, symptoms, and available information on MPNs for patients, and oncology nurses.
Revisiting Guidelines on the Use of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
Challenges in Diagnosing and Managing von Willebrand Disease
Researchers highlighted the current status of diagnostic strategies and laboratory screening tests for von Willebrand disease.
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Relapsed Follicular Lymphoma: Stem Cell Transplantation in the Era of Targeted Therapies
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
A New Standard of Care for Immune-Mediated Thrombotic Thrombocytopenic Purpura?
Combining caplacizumab with therapeutic plasma exchange could decrease hospital stays and treatment costs in the long term.
Recommendations for Optimizing the Use of Group O Red Blood Cells in Transfusions
Group O Rh(D)-negative blood cells can be administered to patients with any ABO Rh(D) type, making them a valuable but limited resource.
Current and Prospective Treatment Strategies for Follicular Lymphoma
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
New Treatment Options Needed for Immune Thrombocytopenia
Current treatment strategies for immune thrombocytopenic purpura are centered on immunomodulation and decreasing platelet destruction
Does Preemptive Stem Cell Transplant Have Value for Patients at Genetic Risk for Leukemia?
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
Pregnant Patients With Lymphoma Can Be Safely and Effectively Treated
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Clinical Management of Inhibitors in Children With Hemophilia
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
From Fatal to Curable: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Want to read more?
Please login or register first to view this content.